2017
Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients
Sun JL, Boyle SH, Samad Z, Babyak MA, Wilson JL, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, O’Connor C, Velazquez EJ, Jiang W. Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. European Journal Of Preventive Cardiology 2017, 24: 591-599. PMID: 28067532, PMCID: PMC6093615, DOI: 10.1177/2047487316686435.Peer-Reviewed Original ResearchMeSH KeywordsAgedCitalopramDisease-Free SurvivalFemaleHumansMaleMental HealthMiddle AgedMultivariate AnalysisMyocardial IschemiaProportional Hazards ModelsRisk AssessmentRisk FactorsSelective Serotonin Reuptake InhibitorsStress, PsychologicalStroke VolumeTime FactorsTreatment OutcomeVentricular Dysfunction, LeftVentricular Function, LeftConceptsMental stress-induced myocardial ischemiaMajor adverse cardiovascular eventsAdverse cardiovascular eventsLeft ventricular ejection fraction changeVentricular ejection fraction changeStable ischemic heart diseaseIschemic heart disease patientsLeft ventricular ejection fractionStress-induced myocardial ischemiaEjection fraction changesVentricular ejection fractionIschemic heart diseaseCardiovascular eventsHeart disease patientsMyocardial ischemiaEjection fractionStudy endpointDisease patientsHeart diseaseMental Stress–Induced Myocardial IschemiaStress-induced left ventricular dysfunctionFuture adverse cardiovascular eventsLeft ventricular dysfunctionHeart failure statusAssociation of indices
2016
Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, Hill JA, Lee KL, Rouleau JL, Prior DL, Ali IS, Maddury J, Golba KS, White HD, Carson P, Chrzanowski L, Romanov A, Miller AB, Velazquez EJ. Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation 2016, 134: 1314-1324. PMID: 27573034, PMCID: PMC5089908, DOI: 10.1161/circulationaha.116.024800.Peer-Reviewed Original ResearchConceptsCoronary artery bypassCause mortalityMedical therapyCardiovascular mortalityYounger patientsEjection fractionHeart failureCABG groupArtery bypassOlder patientsCardiovascular hospitalizationBenefit of CABGEfficacy of CABGCardiopulmonary bypass timeReduced ejection fractionVentricular systolic dysfunctionBaseline ejection fractionCoronary artery diseaseEffect of CABGTen-year outcomesConsistent beneficial effectsMore comorbiditiesSTICH trialBypass timeCardiovascular death
2015
Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction
Samad Z, Shaw LK, Phelan M, Ersboll M, Risum N, Al-Khalidi HR, Glower DD, Milano CA, Alexander JH, O'Connor CM, Wang A, Velazquez EJ. Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction. European Heart Journal 2015, 36: 2733-2741. PMID: 26233850, DOI: 10.1093/eurheartj/ehv343.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseSevere mitral regurgitationEvent-free survival benefitHigher event-free survivalSevere functional mitral regurgitationMV surgerySevere LV dysfunctionEvent-free survivalOutcomes of patientsMitral regurgitationFunctional mitral regurgitationIPW adjustmentSystolic dysfunctionLV dysfunctionSurvival benefitEntire cohortTreatment strategiesSevere left ventricular systolic dysfunctionCoronary artery bypass graft surgeryMultivariable Cox proportional hazards modelsSevere left ventricular dysfunctionArtery bypass graft surgeryLeft ventricular systolic dysfunctionCox proportional hazards modelIsolated MV surgery
2006
The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M. The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction An Analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Journal Of The American College Of Cardiology 2006, 47: 726-733. PMID: 16487836, DOI: 10.1016/j.jacc.2005.09.055.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina PectorisAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAtherosclerosisCaptoprilCardiovascular DiseasesDisease-Free SurvivalDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMyocardial InfarctionRandomized Controlled Trials as TopicRecurrenceStrokeTetrazolesValineValsartanConceptsAngiotensin receptor blockersAcute Myocardial Infarction trialMyocardial Infarction trialAtherosclerotic eventsMyocardial infarctionACE inhibitorsValsartan groupReceptor blockersEnzyme inhibitorsNon-fatal myocardial infarctionAngiotensin-converting enzyme inhibitorAnti-infarction effectSecondary preventive treatmentEffect of valsartanRenin-angiotensin systemBlood pressure differenceEffects of captoprilAcute myocardial infarctionCaptopril groupCombination groupPreventive treatmentLower riskEvidence gapsCaptoprilValsartan
2002
Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank)
O’Connor C, Velazquez EJ, Gardner LH, Smith PK, Newman MF, Landolfo KP, Lee KL, Califf RM, Jones RH. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). The American Journal Of Cardiology 2002, 90: 101-107. PMID: 12106836, DOI: 10.1016/s0002-9149(02)02429-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiac CatheterizationComorbidityCoronary AngiographyCoronary Artery BypassCoronary Artery DiseaseDisease-Free SurvivalFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedOutcome and Process Assessment, Health CareSurvival AnalysisTimeTreatment OutcomeVentricular Dysfunction, LeftConceptsCoronary artery bypass surgeryLong-term outcomesMedical therapyCoronary diseaseIschemic cardiomyopathyNew York Heart Association class IILeft ventricular ejection fractionCox proportional hazards modelDuke University Medical CenterDays of catheterizationInitial cardiac catheterizationMedical therapy armObservational treatment comparisonsCoronary artery bypassHeart failure symptomsMedical therapy groupVentricular systolic dysfunctionArtery bypass surgeryVentricular ejection fractionCoronary artery diseaseEpicardial coronary vesselsProportional hazards modelUniversity Medical CenterCABG groupTherapy arm